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SR31747A is a recently described sigma receptor ligand that binds SR31747A-binding protein 1 (SR-BP) and emopamil-binding
protein (EBP) (also called the sigma1 receptor and the human sterol isomerase (HSI), respectively), and has immunoregulatory and
antiproliferative activities. To further investigate its antitumour activity and focusing on cancers, which are sensitive to the molecule,
we measured the proliferation of different human epithelial breast or prostate cancer cell lines following in vitro and in vivo SR31747A
treatment. Firstly, in vitro, we found that nanomolar concentrations of SR31747A dramatically inhibited cell proliferation in both
hormono-responsive and -unresponsive cancer cell lines. Secondly, tumour development was significantly decreased in mice treated
with SR31747A. In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account
for this activity. Indeed, while competitive experiments indicated that EBP prevails in mediating SR31747A antiproliferative activity, an
analysis of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or
SR-BP expression. These data suggest that additional binding sites may exist. Preliminary binding studies demonstrated that
SR31747A also binds to sigma2, a protein that has not yet been cloned, but which is considered as a potential marker of the
proliferative status of tumour cells. Altogether, our data demonstrate the antitumoural activity of SR31747A both in vitro and in vivo in
two different cancer models, broaden the spectrum of its binding proteins and enhance the potential for further therapeutic
development of the molecule.
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SR31747A is a selective peripheral sigma binding site ligand whose
biological activities include immunoregulation and inhibition of
cell proliferation. For instance, SR31747A was shown to modulate
dramatically proinflammatory and anti-inflammatory cytokine
responses by stimulating SEB (staphylococcal enterotoxin B)- or
LPS (lipopolysaccharide)-induced serum release of IL-10, while
also inhibiting the systemic release of IL-2, IL-4, GM-CSF, IL-6 and
TNFa (Derocq et al, 1995; Bourrie et al, 1996). The antiproliferative
effect of nanomolar SR31747A concentrations was demonstrated in
vitro on a series of various established animal cell lines (Labit-Le
Bouteiller et al, 1998). In humans, SR31747A is known to bind two
proteins with nanomolar affinity. They include SR31747A-binding
protein 1 (SR-BP) and the human sterol isomerase (HIS), also
called EBP for emopamil-binding protein. SR-BP is a 28kDa
protein identical to the sigma1 receptor (Kekuda et al, 1996; Jbilo
et al, 1997). Homology sequence studies indicated that SR-BP is
related to the fungal C8–C7 sterol isomerase encoded by the ERG2
gene (Silve et al, 1996). Both proteins are 30% homologous.
Contrasting with SR-BP, which does not show any enzyme activity
and does not complement the ERG2 gene defect in yeast, EBP is the
human sterol isomerase counterpart of the yeast ERG2 protein
(Hanner et al, 1995; Silve et al, 1996). In humans, the enzyme is a
26kDa, protein, which belongs to the sterol biosynthesis pathway
and catalyses the conversion of 5a-cholesta-8,24-dien-3b-ol
(zymosterol) and 5a-cholesta-8-en-3b-ol (zymostenol, D8-choles-
tenol) to their corresponding D7-isomers. In the yeast Sacchar-
omyces cerevisiae, SR31747A is known to bind ERG2 with
nanomolar affinity and to arrest yeast cell proliferation through
ERG2 inhibition (Silve et al, 1996; Jbilo et al, 1997). In mammals,
even though two different cellular targets for SR31747A have been
identified, the molecule mode of action is not yet fully understood.
Some lines of evidence suggest that the two receptors play a
different role in mediating SR31747A effects. In vitro pharmaco-
logical analyses using an SR-BP-specific ligand indicated that
SR31747A-induced inhibition of T-cell proliferation was quite
consistent with an SR-BP receptor-mediated event (Jbilo et al,
1997), suggesting that the immunoregulatory properties of
SR31747A are predominantly SR-BP dependent. By contrast,
preceding results suggested that the antiproliferative effects of
the SR31747A are mediated by inhibition of cholesterol biosyn-
thesis through the blockade of EBP. Proliferation of a series of
established animal breast, testis and kidney cell lines was shown to
be dramatically altered by SR31747A with a concomitant
accumulation of the D8-cholesterol isomer (Labit-Le Bouteiller
et al, 1998). Cell growth processes are strictly linked to the
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scholesterol biosynthetic pathway, which is a multistep reaction.
The cholesterol needed for new membranes and farnesylation of
ras and G proteins may be derived from endogenous synthesis or
exogenous sources, principally low-density lipoproteins (LDL). As
the inhibition of cholesterol biosynthesis has been shown to reduce
significantly tumour cell growth, this pathway constitutes a highly
promising target for anticancer drug design (Rao et al, 1995). In
this context, SR31747A could be an important potential anti-
tumour agent. To further investigate the SR31747A antiprolifera-
tive effect, we first addressed its potential antitumoural activity
both in vitro and in vivo by measuring the proliferative activity of
different breast and prostate cancer cell lines and the correspond-
ing tumour development in the mouse xenograft model following
SR31747A treatment. Both hormono-dependent and -independent
cells have been tested in order to analyze whether there was a
correlation between the hormonal status and SR31747A efficacy. In
addition, we analysed the role of each receptor in mediating
SR31747A antiproliferative activity using a pharmacological
approach and by investigating potential correlations between
EBP or SR-BP expression and the cellular sensitivity to the
drug.
MATERIALS AND METHODS
Reagents
SR31747A, anti-EBP and anti-SR-BP antibodies (Jbilo et al,
1997; Dussossoy et al, 1999) were produced and provided
by Sanofi Synthe ´labo Research Laboratories (Montpellier,
France). The rabbit anti-EBP polyclonal antibody was targeted
against the N-terminal (2–25) peptide of the human sterol
isomerase (Dussossoy et al, 1999). The anti-SR-BP antibody was
a mouse monoclonal antibody raised against the human
purified SR-BP, also called sigma1 receptors (Jbilo et al, 1997).
Estradiol (E2), tamoxifen, 4-hydroxytamoxifen (OH-TAM), testos-
terone (TEST) and flutamide were from Sigma (France). (+)
Pentazocine was supplied by Research Biochemicals Inc. (Natick,
MA, USA).
Cell lines and culture conditions
Hormono-responsive MCF-7 cells from a breast adenocarcinoma
pleural effusion (Soule et al, 1973) were obtained from Dr M
Lipman’s laboratory (NIH, Bethesda, MD, USA) and cultured in
50% Dulbecco’s minimum essential medium/50% Ham’s F12
(DMEM/F12, 1:1, vv
1) supplemented with 16ngml
1 insulin,
2m ML -glutamine, 10mM Hepes buffer, 50UIml
1 penicillin,
50mgml
1 streptomycin and 10% heat-inactivated fetal calf serum
(FBS). Another MCF-7 cell line, MCF-7AZ was obtained from Dr M
Mareel (Belgium) at passage 360 and was grown in the same
medium as that of MCF-7 cells. MCF-7/LCC1 cells were derived
from MCF-7 cell lines and obtained from Dr M Lippman (V
Lombardi Cancer Center, Georgetown). The MCF-7/LCC1 variant
is hormono-independent (Thompson et al, 1993). MCF-7/LCC1
cells were cultured in phenol red-free DMEM/F12 (1:1, vv
1)
containing 5% steroid-stripped FBS (DCC). The MCF-7 variant
MCF-7LY2 was also provided by Dr M Lipman. This variant cell
line, selected in vitro for its resistance to the growth-inhibitory
effects of the antioestrogen LY117018 (Davidson et al, 1986), was
maintained in DMEM/F12 (1:1, vv
1) supplemented with 10%
FBS. The hormono-unresponsive MDA-MB-321 (Cailleau et al,
1974) and BT-20 (Lasfargues and Ozzello, 1968) cell lines were also
established from a metastatic human breast cancer tumour. MDA-
MB-231 cells were maintained in Leibovitz L15 culture medium
supplemented with 10mM Hepes buffer, 6mgml
1 human insulin,
2m ML -glutamine, 1% nonessential amino acids, 50UIml
1
penicillin, 50mgml
1 streptomycin and 10% FBS. BT20 cells were
maintained in an RPMI medium containing 3mgml
1 human
insulin, 2mML -glutamine, 50UIml
1 penicillin, 50mgml
1
streptomycin and 15% FBS.
The hormono-responsive prostate cancer cell line LNCaP was
originally derived from a patient with metastatic prostate cancer of
pelvic lymph nodes. The hormono-unresponsive DU145 and PC3
cell lines were, respectively, established from brain and bone-
marrow metastase prostatic carcinoma. The three prostatic cell
lines were obtained from the American Type Culture Collection
(Rockville, MD, USA) and cultured in RPMI 1640 medium
supplemented with 10% FBS.
All cells were cultured at 371C in a humid atmosphere of 5% CO2
in air, except for the MDA-MB-231 cell line that was cultured in the
absence of CO2.
Primary culture of normal breast epithelial cells (NBECs)
Epithelial cells were grown from tissue specimens obtained, after
informed consent, from nine women between 16 and 50 years of
age who had undergone reduction mammoplasty for cosmetic
reasons. Normal state of breast tissues was controlled by
histopathological examination. After mechanical dissociation with
scissors, tissues were incubated at 371C with constant shaking in a
medium containing 150Uml
1 hyaluronidase (Sigma-Aldrich,
France) and 250–500Uml
1 collagenase (Sigma-Aldrich, France).
Digestion was monitored under an inverted microscope. Released
organoids were isolated by density gradient centrifugation for
30min at 800g, using 1.077gml
1 lymphocyte separation medium.
Organoids were then plated in a DMEM/F12 (1:1, vv
1)
medium containing 5% FBS, 10mgml
1 insulin, 510
–6M cortisol
(Sigma-Aldrich, France), 2ngml
1 EGF (Euromedex, France),
100ngml
1 cholera toxin (Sigma-Aldrich, France), 2mML -
glutamine, 50Uml
1 penicillin and 50mgml
1 streptomycin (B1
medium). Cells were maintained at 371C in a humid atmosphere of
5% CO2 in air. When cells attained preconfluence, the medium
was replaced by B2 medium, which differed from B1 medium by its
lower CaCl2 concentration (0.060 vs 1.05mM). Under these
conditions, cells released floating daughter cells that were
collected and replaced in the B1 medium. The epithelial phenotype
of the cultured cells was verified by immunocytochemistry
of specific markers, as previously described (Mosmann,
1983).
Cell growth experiments
Cell growth was determined in six- or 24-well culture plates. Cells
were seeded in their respective culture media at densities that
varied as a function of their proliferation rate. Cells were allowed
to grow for 2 days and then treated for 5–6 days with different
SR31747A concentrations. Treatments for breast cancer cell lines
were performed in 0.1% FBS, and 1% FBS for prostatic cancer cell
lines. Media were renewed every 2 days. At the end of treatment,
cells were harvested and the cell number was determined using a
cell counter. Cell proliferation was also evaluated by a colorimetric
method based on the cellular conversion of tetrazolium salt (MTT)
into a blue formazan product (Feulgen and Rossenbech, 1924). The
SR31747A antiproliferative effect was compared with that of OH-
TAM in 0.1% FBS or flutamide in 1% FBS. To study SR31747A
route of action, either 10
–5and 10
–6M (+) pentazocine or 1, 2, 10
and 20mgml
1 cholesterol was added to 0.1% FBS when analysing
breast cancer cell line responses (MCF7 and MDA-MB-231) or 1%
when analysing prostate cancer cell line responses (DU145 and
LnCaP), treatment lasted 4 days. These compounds were used to
analyse specifically the route of action of SR31747A, as they make
it possible to discriminate between EBP and SR-BP. Pentazocine is
a specific SR-BP ligand, while the use of cholesterol reverses the
blockade of EBP.
SR31747A inhibits breast and prostrate cancer cell growth
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sDetermination of EBP and SR-BP expression levels by flow
cytometry
The analysis was performed with the cell lines used in the in vitro
antiproliferative test. Normal cells included were lymphocytes and
monocytes. After growth in the medium containing 0.1 or 1%
serum for breast or prostate cell lines, respectively, 10
6 cells were
fixed overnight at room temperature in 500ml of 1% paraformal-
dehyde in PBS. After washes in PBS, cells were permeabilised in
PBS containing 1% BSA and 0.1% saponin. Expression of both
proteins was determined according to Vogt et al, (1989). The EBP
antigen number was determined by direct immunofluorescence
using an FITC-conjugated rabbit polyclonal anti-EBP antibody and
standard FITC-conjugated beads (DAKO). The SR-BP expression
level was measured by indirect immunofluorescence assay using
1mg murine monoclonal anti-SR-BP antibody and FITC-conju-
gated anti-mouse immunoglobulins (DAKO). The SR-BP antigen
number was calculated using a quantitative immunofluorescence
assay kit, according to the manufacturer’s instructions (DAKO).
Experiments were analysed with a FACScan flow cytometer
(Becton-Dickinson, France).
In vivo studies
The present animal experiments complied with the European and
French laws and with the guiding principles for experimental
procedures as set forth in the Declaration of Helsinki and are in
accordance with the UK Guidelines for the Welfare of Animals in
Experimental Neoplasia (UKCCCR, 1998). Homozygous female
athymic nude mice (nu+/nu+, balb/c strain) were obtained from
Iffa-Credo (L’Arbresle, France). Animals were housed and main-
tained in pathogen-limited conditions under filtered laminar air
flow hoods at 22–251C with a 12h light:12h darkness photo-
period. Sterilised food and water were provided ad libitum. Six-
week-old mice were used to initiate the experiments. Cells from
preconfluent monolayers of tumoural cell lines were harvested,
then washed and resuspended in PBS supplemented with 1mM
CaCl2.1 – 510
6 cells in 200ml of cell suspension were inoculated
s.c. in both flanks of animals through a 25-gauge needle. Animal
treatments were initiated the following day. All compounds were
dissolved in ethanol, Tween 80 and 0.9% NaCl (1:1:20, vv
1).
Control animals (10 mice) received i.p. the vehicle, whereas the
animals of the studied groups (10 mice per group) were given i.p.
daily doses of SR31747A (25mgkg
1), tamoxifen (1mgkg
1),
estradiol (100mgkg
1), testosterone (100mgkg
1) or flutamide
(2.5mgkg
1), alone or in combination as indicated. A dose of
25mg SR31747A, once a day, was chosen for in vivo studies as this
is highly sufficient to maintain an effective plasma level and to
saturate all the binding sites (data not shown). Tumours were
measured with Vernier calipers at different times. Two perpendi-
cular diameters were recorded, and the tumour volume was
calculated according to the formula: (width)
2/2length/2. After
2–3 months of treatment, the animals were killed by cervical
dislocation and tumours were removed post mortem, weighed and
stored in liquid nitrogen. Values relative to tumour size are the
mean values obtained for each experimental group (total tumour
load divided by the number of tumours). For comparative
purposes, tumour sizes or weights in each group are reported in
Results as a percentage of the size or weight of the tumour
observed in the control group at the end of treatment. Experiments
were performed twice.
Statistical analysis
All values are expressed as mean7s.d. of several determinations.
The Student’s t-test was used for comparison of the experimental
data. *, Po0.05; **, Po0.01.
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Figure 1 Antiproliferative effect of SR31747A on different breast
cancer epithelial cell lines and on NBECs in primary culture. Treatments
with different SR31747A concentrations were performed in 0.1% FBS, as
described in Materials and Methods. Representative curves are shown.
effects on hormono-responsive MCF-7 cells (A), hormono-unresponsive
MDA MB 231 cells (B), or NBECs (C). The results are expressed as a
percentage of MTT conversion measured in untreated cells.
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sRESULTS
Effect of SR31747A on the proliferation of human breast
cancer cell lines
The effect of SR31747A on cell proliferation was first evaluated in
vitro on a series of human breast epithelial cancer cell lines.
Representative data are reported in Figure 1A, B and demonstrate
that SR31747A clearly induced concentration-dependent inhibition
of cell proliferation, irrespective of the cell line considered, that is
either hormono-responsive (Figure 1A) or -unresponsive
(Figure 1B) cells. The antiproliferative potency of SR31747A varied
with the cell line considered and showed an IC50 ranging from 10
–10
to 10
–8M (Table 1). While most of the MCF-7-derived cell lines
exhibited an IC50 of 10
–9–10
–8M for SR31747A, MCF-7LY2 cells
appeared to be the most sensitive cells since 50% cell growth
inhibition was observed with 10
–11–10
–10M SR31747A. The
proliferation of the hormono-independent MDA-MB231 and BT-
20 cells was similarly affected by SR31747A, with an IC50 of 10
–8
and 10
–9M, respectively (Table 1). For comparative purposes, we
tested the effect of the antioestrogen OH-TAM on cell prolifera-
tion. As reported in Table 1, the OH-TAM, which also blocks EBP
activity, appeared to be more efficient than SR31747A at inhibiting
the proliferation of the hormono-sensitive MCF-7 and MCF-7AZ
cell lines. By contrast, the proliferation of the hormono-
independent MDA-MB231 and BT-20 cells was little affected by
OH-TAM. High concentrations of OH-TAM are required to obtain
significant growth inhibition (10
–6M, Table 1). As expected, the
anti-oestrogen-resistant cell lines, MCF-7LCC1 and MCF-7LY2,
appeared less responsive to OH-TAM regarding cell proliferation
compared with MCF-7 or MCF-7 7AZ (Table 1).
In addition, the effect of SR31747A on cell proliferation was
analysed on NBECs in primary culture. The results illustrated in
Figure 1C demonstrated that NBECs were less sensitive than the
tumoural cell lines to the growth-inhibitory activity of SR31747A, since
a 50% cell growth reduction required 510
–7M SR31747A (Table 1).
Effect of SR31747A on the proliferation of human prostatic
cancer cell lines
The antiproliferative activity of SR31747A was further tested in
vitro on three different human prostatic cancer cell lines. The
results presented in Figure 2 and Table 1 indicate that, similar to
breast cancer cells, the growth of prostatic cell lines was inhibited
by SR31747A in vitro. Moreover, the growth inhibitory activity of
SR31747A appeared to be dose dependent, and 50% growth
inhibition of LNCaP and DU145 cells was obtained with 10
–8M
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Figure 2 Antiproliferative effect of SR31747A on prostatic cancer epi-
thelial cell lines. Treatments with SR31747A were performed in low
lipid serum concentrations (1% FBS), as described in Materials and
methods. Effects on hormono-responsive LNCaP cells (A), and on
hormono-unresponsive DU145 (B) and PC3 (C) cells. The results are
expressed as a percentage of MTT conversion measured in untreated
cells.
Table 1 Effect of SR31747A and either OH-TAM or Flutamide on the
proliferation of breast cancer epithelial cell lines, NBECs and prostatic
cancer epithelial cell lines
IC50, molar concentrations
Breast cancer cell lines SR 31747A OH-TAM
MCF-7 210
9–10
8 10
11
MCF7-7AZ 10
9–10
8 310
11
MCF-7LCC1 10
9 510
7
MCF-7LY2 510
11–10
10 510
7
MDA-MB-231 10
8–510
8 310
6
BT20 10
9 10
6
NBECs 510
7 10
8
Prostate cancer cell lines SR 31747A Flutamide
LNCaP 10
8 10
6
DU145 10
8 >10
6
PC3 10
7 >10
6
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the two other tested prostatic cell lines, in that 50% inhibition was
obtained with 10
–7M SR31747A. The effect of the antiandrogen
flutamide on cell proliferation was compared with that of
SR31747A. Interestingly, SR31747A appeared to be more efficient
than flutamide in inhibiting the proliferation of the hormono-
sensitive LNCaP cells: a 100-fold higher flutamide concentration
was required to obtain a similar inhibitory effect (Table 1). As
expected and in contrast with LNCaP, the proliferation of the two
hormono-unresponsive DU145 and PC3 cell lines was not affected
by the flutamide treatment regardless of the concentration tested.
The IC50 of flutamide on LNCaP lines is 10
–6M, in accordance with
previous reports (Evans et al, 2001; Mitchell et al, 2002).
Analysis of the role of each receptor in mediating
SR31747A antiproliferative activity
SR31747-induced proliferation inhibition is predominantly
mediated by EBP We tested whether the inhibition of cell
proliferation is mediated by either SR-BP or EBP. Firstly, to
discriminate between the two proteins, we used the sigma 1 ligand
(+) pentazocine that binds to SR-BP, but does not bind EBP (Jbilo
et al, 1997). As shown in Figure 3A, the addition of (+) pentazocine
did not affect the antiproliferative activity of SR31747A, even when
10
–5M (+) pentazocine was added. Representative curves are
shown from breast cancer cell lines, MCF7 and MDA-MB231 cells,
and from prostate cancer cell lines, DU-145 and LnCaP (Figure 3A).
(+) Pentazocine alone does not affect cell proliferation (data not
shown). Secondly, if SR31747A-induced proliferation arrest is
because of EBP inhibition, then this effect may be reversed when
adding cholesterol. The involvement of EBP was demonstrated as
the addition of cholesterol was shown to concentration-depen-
dently counteract the SR31747A antiproliferative effect. Represen-
tative curves are shown from breast cancer cell lines, MCF7 and
MDA MB 231 cells, and from prostate cancer cell lines, DU-145 and
LnCaP (Figure 3B). The antiproliferative effect of SR31747A was
partially reduced by adding cholesterol, even at the maximum
concentration tested: 20mgml
1 cholesterol restored cellular
proliferation by 90%. Higher percentages were not achieved when
using higher cholesterol concentrations (data not shown).
Cholesterol itself, in the absence of SR31747, has no effect (data
not shown).
Determination of EBP and SR-BP expression in human breast and
prostate cancer epithelial cells In an attempt to correlate the
growth-inhibitory activity of SR31747A with the presence of its
receptors, we evaluated EBP and SR-BP expression levels by flow
cytometry using specific antibodies in the breast and prostatic
cancer cell lines used in this study. Our results reported in
Figure 4A indicate that, except for MCF-7 LY2 cells exhibiting very
low levels of SR-BP, all cells examined expressed significant levels
of both EBP and SR-BP. Interestingly, significantly higher
expression levels in comparison with normal cells were obtained,
as quantification of SR-BP and EBP showed receptor densities
ranging from 30000 to 280000sites cell
1, whereas in normal cells
(in lymphocytes or monocytes) EBP or SR-BP density was lower
50000sitescell
1. Both SR-BP and EBP had expression levels that
varied according to the cell line studied. In the breast cancer MCF-
7 cell line and MCF-7-derived cell lines, significant amounts of
both EBP and SR-BP were obtained from 40000 to 280000 and
5000 to 80000sitescell
1, respectively. By contrast, BT20 and
MDA-MB231 cell lines exhibited higher expression levels of SR-BP
than EBP, from 75000 to 90000sitescell
1 compared with
40000sitescell
1, respectively. In prostatic cancer cell lines,
40000EBPsitescell
1 were measured. Whereas similar SR-BP
densities were measured in the PC3 cell line, LNCaP and DU145
were found to express a dramatically greater number of SR-BP
(150000 and 190000sitescell
1, respectively). To determine
whether there is a correlation between the sensitivity to
SR31747A treatment and the cellular receptor content, we plotted
the SR31747A IC50 levels obtained for each cell line (noted in
Table 1) against the corresponding SR-BP density (Figure 4B) or
EBP density (Figure 4C). No significant correlations were
observed. Moreover, there were no significant correlations when
considering the EBP/SR-BP content ratio (data not shown).
Effect of SR31747A on tumour development in vivo
To determine whether SR31747A has any antitumoural activity in
vivo, mammary and prostatic tumoural cell lines were injected s.c.
into nude mice on two opposite sites in the flank. SR31747A
MDA-MB-231
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Figure 3 Effect of pentazocine (A) or cholesterol (B) on the inhibition
of mitogenesis in different cell lines induced by SR31747A. (A) Two
concentrations of (+) pentazocine were tested: control (J), 10
6 M (K)
and 10
5 M (&). (B) Four cholesterol concentrations were tested: control
(J), 1mgml
1 (K), 2mgml
1 (&), 10mgml
1 (’) and 20mgml
1 (W).
Treatments were performed in low lipid serum concentrations (0.1% FBS
for breast cancer cell lines or 1% for prostate cell lines). Representative
curves are shown: MCF7, MDA-MB-231 for breast cancer cell lines, and
DU145 and PC3 for prostate cancer cell lines. The results are expressed as
a percentage of MTT conversion measured in untreated cells.
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streatments (25mgkg
1) given daily for 2–3 months did not cause
any significant body weight loss relative to controls.
Effect of SR31747A on breast tumour development in vivo First,
we tested the impact of SR31747A on tumour development
originating from hormono-responsive MCF-7 cells (Figure 5A).
MCF-7 cells formed tumours in only 20% of control animals.
When animals were treated daily with E2, more than 90% of mice
developed tumours (data not shown). Whereas the antioestrogen
TAM partially antagonise the tumoural activity of E2, SR31747A
was unable to affect the incidence and size of MCF-7 tumours in
E2-treated animal groups (Figure 5A). We investigated the
potential synergy between SR31747A and TAM in vivo by
monitoring the development of MCF7 cell-derived tumours when
mice were treated with a combination of both compounds. As
mentioned above, all animal groups received daily injection of 2mg
E2 to promote tumour formation and growth. As expected, the
tumour size (Figure 5B) appeared to be markedly reduced in the
presence of the antioestrogen. However, under 1mgkg
1 TAM
treatment, tumours in the vehicule-treated group started to regrow
50–55 days after the beginning of treatment. This process was
totally prevented when TAM and SR31747A are associated until the
end of treatment (70 days, Figure 5B). Moreover, under these
experimental conditions, the addition of SR31747A was even able
to induce tumour regression after 30–40 days of treatment
(Figure 5B).
While SR31747A alone is not efficient at inhibiting MCF-7 cell-
derived tumour growth in vivo, the development of tumours that
formed after injection of MDA-MB231 cells appeared to be
modified substantially under SR31747A treatment. As shown in
Figure 5C, SR31747A tended to reduce the growth of tumours
derived from the MDA-MB231 cells, by 60% at 67 days and 70% at
85 days compared to control. At the end of treatment (92 days),
tumours were 60% lighter in weight in animals treated with
SR31747A than in control (Figure 5D).
Effect of SR31747A on prostatic tumour development
in vivo
The impact of SR31747A on the development of tumours
originating from hormono-independent prostatic carcinomas
DU145 and PC3 was tested (Figure 6). In both cases, tumour
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sdevelopment was significantly slowed down. A 25mgkg
1 dose of
SR31747A treatment resulted in a reduction of both the tumour
size (Figure 6A, C) and tumour weight (Figure 6B, D), that is, by 50
and 40% for PC3 and DU145 tumours, respectively. SR31747A
treatment did not affect the body weight. In this model, we also
tested a putative synergistic effect of SR31747A with the anti-
androgen flutamide. When considering the development of
hormono-dependent LNCaP cells, we noted that SR31747A
(25mgkg
1) and flutamide (2.5mgkg
1) synergistically inhibited
LNCaP cell proliferation in vivo. Tumour size was reduced by 45
and 55% following SR31747A or flutamide treatment, respectively
(Figure 7). A combined SR31747A and flutamide treatment
resulted in a 70% reduction in tumour size at day 75 (Figure 7).
DISCUSSION
Previous studies have clearly shown that SR31747A has immuno-
suppressive properties. Here we further document the in vitro
antiproliferative effect of SR31747A, and demonstrate for the first
time that the molecule also inhibits proliferation in vivo in the
mouse xenograft model. Our results showed that SR31747A
inhibited cell proliferation of either hormono-responsive or
hormono-unresponsive human cancer cell lines in vitro.W e
obtained evidence on the nanomolar potency of the SR31747A
molecule in inhibiting the proliferation of breast cancer MCF7
cells, MCF-7 derived cells, MDA MB 231 and BT20 cells. This
inhibitory effect of SR31747A was also reproduced in both
hormono-responsive (LNCaP) and -unresponsive (DU-145 and
PC3) prostate cancer cell lines. Moreover, in vivo, using the mouse
xenograft model, SR31747A treatment was shown to reduce
significantly tumour development when induced by the inocula-
tion of human breast or prostatic cancer cell lines in nude mice. No
toxicity was noted as the animal body weight was not affected
during treatment. Interestingly, we also found that SR31747A: (i)
prevents the escape of breast cancer cells under long-term
tamoxifen treatment and (ii) synergises with flutamide.
The nanomolar efficacy of SR31747A in inhibiting cell
proliferation in vitro is in favour of a receptor-mediated event.
In humans, SR31747A is known to bind two proteins. In this
context, it is crucial to identify which protein mediates the
antiproliferative activity of the molecule in mammals. To explore
SR-BP and EBP involvement, the antiproliferative effect of
SR31747A was challenged with either (+) pentazocine, an SR-BP-
specific ligand, or cholesterol. The inhibitory effect of SR31747A
was not antagonised by the addition of the competitive SR-BP
ligand (+) pentazocine, whereas the addition of cholesterol was
found to reduce partially and dose dependently the SR31747A
inhibitory effect. These data are in accordance with previous
results (Labit-Le Bouteiller et al, 1998) and support the involve-
ment of EBP in mediating the antiproliferative effect of SR31747A.
However, some lines of evidence suggest that EBP may not be the
only protein involved. First, the antiproliferative effect of
SR31747A was partially prevented by cholesterol. Second, if the
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unresponsive MDA MB 231 (C,D) breast cancer cell lines in vivo.( A)
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tamoxifen (TAM). (B) SR31747A synergises with tamoxifen to inhibit
MCF-7 cell proliferation in vivo. Mice bearing MCF-7 cells were treated with
2mg E2 to induce tumour cell proliferation. These mice were then treated
or not (J) with 1mgkg
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Animals per group: 10 and experiments have been performed twice.
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Figure 6 Effect of SR31747A treatment on the development of
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santiproliferative effect of SR31747A is exclusively a consequence of
the sterol isomerase inhibition, then the sensitivity to SR31747A
may be correlated with the cellular EBP content. To test this
hypothesis, we investigated the expression levels of both SR-BP
and EBP in the series of cancer cell lines included in our study. We
did not obtain a significant correlation between the IC50 and the
EBP content. Cell lines that express markedly different levels of
EBP, such as MCF-7-AZ and LNCaP or DU145, were found to
exhibit sensitivity similar to SR31747A. The inverse was also
observed. Similar results were obtained with SR-BP. Two different
hypotheses may be put forward to explain this phenomenon. First,
when analysing EBP and SR-BP subcellular expression, both
proteins were previously shown to be colocalised at the
endoplasmic reticulum and nuclear envelope (9), thus indicating
that EBP and SR-BP may be mutually involved in mediating
SR31747A antiproliferative activity. However, no physical inter-
action between both proteins has been observed so far, and our
data indicate that the cellular sensitivity to SR31747A does not
depend on either EBP or SR-BP levels or any combination of these
two proteins. Second, the possibility that additional binding sites
for SR31747A may exist in humans cannot be overlooked.
Interestingly, preliminary binding studies have shown that 45nM
SR31747A displaced
3H DTG binding to sigma2 (H Vidal, personal
communication). Sigma2 receptors are proteins of approximately
21kDa whose sequence is unknown. To date, the protein proper-
ties have been investigated using specific pharmacological tools.
Although its function remains elusive, some reports suggest that it
may play a role in tumourigenesis. Using specific ligands that can
discriminate between SR-BP and sigma2, sigma2 receptors were
found to be overexpressed in tumour cells as compared with their
normal counterparts, including breast, neural, lung, prostate and
melanoma tumours (Vilner et al, 1995). In addition, sigma2
receptor expression was found to be correlated with the
proliferative status of human breast tumours (Mach et al, 1997)
and solid tumours (Wheeler et al, 2000). It has thus been
demonstrated that sigma2 receptor binding ligands may be used
for in vivo noninvasive diagnostic receptor imaging (John et al,
1999). In this context, it would be essential to identify the sigma2
protein. Further studies are needed to investigate the biological
responses associated with SR31747A binding on sigma2 and to
define accurately the SR31747A mode of action. It would therefore
be very useful to develop cell lines lacking one or several SR31747A
receptors. MCF-7-LY2 cells that lack detectable levels of SR-BP
could be of interest.
In conclusion, we report for the first time that, in addition to its
immunoregulatory property, SR31747A exhibits antiproliferative
activity both in vitro and in vivo on a series of human breast and
prostate cancer cell lines. In order to document accurately
SR31747A antitumoural activity, further studies are now required
to decipher its mode of action, to identify accurately the sigma2
protein, and to define the separate roles of each SR-BP.
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